ArticleCureus2024
Comparison of the Mitotic Count With Various Proliferative Markers for the Effective Differentiation of Benign, Borderline, and Malignant Phyllodes Tumors.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Phyllodes tumors of the breast are categorized as benign, borderline, or malignant based on the WHO classification, which provides comprehensive criteria for determination, such as stromal cell density, stromal cell atypia, mitotic count, borderline status, and presence of ectopic stromal components. The present study was conducted to determine whether there is a proliferative marker superior to mitotic count. Methods The cohort comprised 47 benign, 13 borderline, and 16 malignant phyllodes tumors classified according to the WHO criteria. Various cell cycle-related proteins, including Ki-67, Cyclin A2, Cyclin B1, Cyclin E, phospho-histone H3, and Survivin, were used as proliferation markers. Cutoff values, sensitivity and specificity, and positive predictive value (PPV) were determined using the receiver operator characteristic (ROC) analysis. Results When comparing sensitivity and specificity using cutoff values to differentiate malignant phyllodes tumors from benign and borderline phyllodes tumors separately, only mitotic count alone showed a value exceeding 0.9. Additionally, the mitotic count showed a PPV greater than 0.8 in all three types of differentiation. However, when differentiating between benign and borderline phyllodes tumors, none of the proliferative indices, including mitotic count, exhibited a value greater than 0.9 for both sensitivity and specificity, and the PPV for borderline tumors did not exceed 0.4. Conclusion These findings suggest that mitotic count is the most reliable index for assessing proliferation, for differentiation of malignant from benign or borderline phyllodes tumors. Furthermore, it was revealed that criteria other than the proliferation index play a crucial role in distinguishing between benign and borderline phyllodes tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.